in the absence of a submission from the holder of the marketing authorisation:
pitolisant (Wakix®) is not recommended for use within NHSScotland.
Indication under review: To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by, or who have not tolerated, OSA primary therapy, such as continuous positive airway pressure (CPAP).
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice236KB (PDF)
Medicine details
- Medicine name:
- pitolisant (Wakix)
- SMC ID:
- SMC2662
- Indication:
To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by, or who have not tolerated, OSA primary therapy, such as continuous positive airway pressure (CPAP).
- Pharmaceutical company
- Bioprojet UK Limited
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 March 2024